In a multi-dose phase 1 clinical trial, FT538 was used for the treatment of AML, in combination with daratumumab, a CD38-targeted monoclonal antibody therapy used for the treatment of multiple myeloma (NCT04614636). This evidence concerns the gene CD38 and AL amyloidosis.